Contribute Try STAT+ Today

Ovid Therapeutics’ experimental drug for a devastating rare disease proved no better than placebo in a pivotal clinical trial, the company said Tuesday, a bitter disappointment for families dealing with the untreatable condition.

The study enrolled 97 children with Angelman syndrome, a rare genetic disorder that causes seizures and severe cognitive impairment, and randomized them to receive either Ovid’s drug, OV101, or placebo. After 12 weeks, a daily oral dose of OV101 was no better than placebo at improving the symptoms of Angelman, which include impaired sleep, inability to speak, delayed motor development, and intellectual disability.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.